InVivo Therapeutics to Present at Ladenburg Thalmann 2017 Healthcare Conference
September 20 2017 - 08:00AM
Business Wire
InVivo Therapeutics Holdings Corp. (NVIV) today announced
that Mark Perrin, Chief Executive Officer and Chairman, will
present at the Ladenburg Thalmann 2017 Healthcare Conference on
Tuesday, September 26, 2017 at 12:00pm ET at the Sofitel New York
Hotel, in Manhattan. Mr. Perrin’s presentation will provide an
overview of the company and discuss recent updates to the company’s
Neuro-Spinal Scaffold™ program.
A live webcast of the presentation will be available at
http://wsw.com/webcast/ladenburg3/nviv/ and a webcast replay will
be available at the same address approximately one hour after the
live webcast presentation. Please log in 5-10 minutes before the
event to ensure a timely connection.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a clinical-stage
biomaterials and biotechnology company with a focus on treatment of
spinal cord injuries. The company was founded in 2005 with
proprietary technology co-invented by Robert Langer, Sc.D.,
Professor at Massachusetts Institute of Technology, and Joseph P.
Vacanti, M.D., who then was at Boston Children’s Hospital and who
now is affiliated with Massachusetts General Hospital. In 2011, the
company earned the David S. Apple Award from the American Spinal
Injury Association for its outstanding contribution to spinal cord
injury medicine. In 2015, the company’s investigational
Neuro-Spinal Scaffold™ received the 2015 Becker’s Healthcare Spine
Device Award. The publicly-traded company is headquartered in
Cambridge, MA. For more details, visit
www.invivotherapeutics.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170920005356/en/
InVivo Therapeutics Holdings Corp.Heather Hamel,
617-863-5530Investor
RelationsInvestor-relations@invivotherapeutics.com
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Feb 2024 to Mar 2024
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Mar 2023 to Mar 2024